Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 146Carcinoma, Non-Small-Cell Lung 112Carcinoma, Renal Cell 74Neoplasm Metastasis 53Carcinoma, Hepatocellular 51Squamous Cell Carcinoma of Head and Neck 50Lung Neoplasms 48Colorectal Neoplasms 34Pancreatic Neoplasms 30Neoplasms 30Hodgkin Disease 30Urinary Bladder Neoplasms 24Sarcoma 23Brain Neoplasms 23Stomach Neoplasms 22Head and Neck Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Carcinoma, Transitional Cell 20Glioblastoma 19Recurrence 17Colonic Neoplasms 17Kidney Neoplasms 16Uveal Melanoma 15Small Cell Lung Carcinoma 15Multiple Myeloma 15Esophageal Neoplasms 15Carcinoma, Squamous Cell 14Skin Neoplasms 13Leukemia, Myeloid, Acute 13

Interventions

atezolizumab 2irinotecan sucrosofate 1cobimetinib 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Immunoglobulin G 1Fluorouracil 1Famotidine 1Disulfides 1Diphenhydramine 1Dexamethasone 1DNA Fingerprinting 1Chemoradiotherapy 1Calcium Dobesilate 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Mucinous × Nivolumab × Clear all
NCT05504252 2026-01-07

METIMMOX-2

University Hospital, Akershus

Phase 2 Active not recruiting
80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡